ALHEMO
As listed in the register: ALHEMO 60 mg/1,5 mL, solution injectable en stylo prérempli
60 mg · solution injectable
- Prescription only
- Active substance
- Concizumab
- Made by
- NOVO NORDISK (DANEMARK)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Alhemo). It describes the substance, not this exact product.
Concizumab-mtci is a monoclonal antibody antagonist of endogenous Tissue Factor Pathway Inhibitor (TFPI).
Through the inhibition of TFPI, concizumab-mtci acts to enhance FXa production during the initiation phase of coagulation which leads to improved thrombin generation and clot formation with the goal of achieving hemostasis in patients with Hemophilia A or B regardless of their inhibitor status.
Concizumab-mtci is expected to be metabolized into small peptides by catabolic pathways.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-07-01
Safety of the active substance
From the US prescribing label for the same active substance (Alhemo). It describes the substance, not this exact product.
- Alhemo is contraindicated in patients with a history of known serious hypersensitivity to Alhemo or its components or the inactive ingredients [see Warnings and Precautions ( 5.1 )and Description ( 11 )].
The most frequently reported adverse reactions (incidence ≥5%) were injection site reactions, headache and urticaria.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | NOVO NORDISK (DANEMARK) |
|---|---|
| Active substance | Concizumab |
| Strength | 60 mg |
| Form | solution injectable |
| Route | sous-cutanée |
| Dispensing (as stated by the register) | prescription hospitalière · liste I |
| Marketed | Yes, according to the register |
| Reinforced monitoring | Yes — under reinforced monitoring, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/24/1881 |
| Name in the register | ALHEMO 60 mg/1,5 mL, solution injectable en stylo prérempli |
| Packs | 1 cartouche(s) en verre dans stylo pré-rempli de 1,5 ml |
| CIS | 62881990 |
| CIP13 | 3400930305096 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution injectable2 products
- 60 mg
- 150 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.